Press release
May 1, 2026
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (CTNM)
SAN DIEGO --(BUSINESS WIRE)--May 1, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that